Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
09
2020
accepted:
08
03
2021
entrez:
23
3
2021
pubmed:
24
3
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Several studies have proposed personalized strategies based on women's individual breast cancer risk to improve the effectiveness of breast cancer screening. We designed and internally validated an individualized risk prediction model for women eligible for mammography screening. Retrospective cohort study of 121,969 women aged 50 to 69 years, screened at the long-standing population-based screening program in Spain between 1995 and 2015 and followed up until 2017. We used partly conditional Cox proportional hazards regression to estimate the adjusted hazard ratios (aHR) and individual risks for age, family history of breast cancer, previous benign breast disease, and previous mammographic features. We internally validated our model with the expected-to-observed ratio and the area under the receiver operating characteristic curve. During a mean follow-up of 7.5 years, 2,058 women were diagnosed with breast cancer. All three risk factors were strongly associated with breast cancer risk, with the highest risk being found among women with family history of breast cancer (aHR: 1.67), a proliferative benign breast disease (aHR: 3.02) and previous calcifications (aHR: 2.52). The model was well calibrated overall (expected-to-observed ratio ranging from 0.99 at 2 years to 1.02 at 20 years) but slightly overestimated the risk in women with proliferative benign breast disease. The area under the receiver operating characteristic curve ranged from 58.7% to 64.7%, depending of the time horizon selected. We developed a risk prediction model to estimate the short- and long-term risk of breast cancer in women eligible for mammography screening using information routinely reported at screening participation. The model could help to guiding individualized screening strategies aimed at improving the risk-benefit balance of mammography screening programs.
Sections du résumé
BACKGROUND
Several studies have proposed personalized strategies based on women's individual breast cancer risk to improve the effectiveness of breast cancer screening. We designed and internally validated an individualized risk prediction model for women eligible for mammography screening.
METHODS
Retrospective cohort study of 121,969 women aged 50 to 69 years, screened at the long-standing population-based screening program in Spain between 1995 and 2015 and followed up until 2017. We used partly conditional Cox proportional hazards regression to estimate the adjusted hazard ratios (aHR) and individual risks for age, family history of breast cancer, previous benign breast disease, and previous mammographic features. We internally validated our model with the expected-to-observed ratio and the area under the receiver operating characteristic curve.
RESULTS
During a mean follow-up of 7.5 years, 2,058 women were diagnosed with breast cancer. All three risk factors were strongly associated with breast cancer risk, with the highest risk being found among women with family history of breast cancer (aHR: 1.67), a proliferative benign breast disease (aHR: 3.02) and previous calcifications (aHR: 2.52). The model was well calibrated overall (expected-to-observed ratio ranging from 0.99 at 2 years to 1.02 at 20 years) but slightly overestimated the risk in women with proliferative benign breast disease. The area under the receiver operating characteristic curve ranged from 58.7% to 64.7%, depending of the time horizon selected.
CONCLUSIONS
We developed a risk prediction model to estimate the short- and long-term risk of breast cancer in women eligible for mammography screening using information routinely reported at screening participation. The model could help to guiding individualized screening strategies aimed at improving the risk-benefit balance of mammography screening programs.
Identifiants
pubmed: 33755692
doi: 10.1371/journal.pone.0248930
pii: PONE-D-20-29968
pmc: PMC7987139
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248930Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Stat Methods Med Res. 2018 Aug;27(8):2264-2278
pubmed: 27895266
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
pubmed: 2593165
PLoS One. 2014 Feb 03;9(2):e86858
pubmed: 24498285
Breast Cancer Res Treat. 2016 Oct;159(3):513-25
pubmed: 27565998
J Clin Epidemiol. 2001 Aug;54(8):774-81
pubmed: 11470385
N Engl J Med. 2005 Jul 21;353(3):229-37
pubmed: 16034008
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
J Natl Cancer Inst. 2006 Sep 6;98(17):1204-14
pubmed: 16954473
Breast Cancer Res. 2008;10(4):R55
pubmed: 18598349
Cancer. 1985 Jun 1;55(11):2698-708
pubmed: 2986821
Radiology. 2016 Aug;280(2):379-86
pubmed: 26878225
JAMA. 2006 Jun 21;295(23):2727-41
pubmed: 16754727
Eur J Radiol. 2019 Jan;110:81-87
pubmed: 30599878
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
BMC Med Inform Decis Mak. 2008 Oct 27;8 Suppl 1:S6
pubmed: 19007443
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
PLoS Med. 2018 Sep 4;15(9):e1002644
pubmed: 30180161
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Br J Cancer. 2004 Oct 18;91(8):1580-90
pubmed: 15381934
Ann Oncol. 2008 Apr;19(4):614-22
pubmed: 18024988
Stat Med. 2016 Dec 10;35(28):5267-5282
pubmed: 27523800
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
pubmed: 9747868
Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):889-97
pubmed: 25824444
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
JAMA Intern Med. 2014 Mar;174(3):448-54
pubmed: 24380095
Br J Cancer. 2019 Jul;121(1):76-85
pubmed: 31114019
Ann Oncol. 2010 May;21 Suppl 3:iii43-51
pubmed: 20427360
Breast Cancer Res. 2017 Mar 14;19(1):29
pubmed: 28288659
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
N Engl J Med. 1985 Jan 17;312(3):146-51
pubmed: 3965932
J Epidemiol Community Health. 2003 Aug;57(8):634-8
pubmed: 12883073
J Clin Oncol. 2015 Oct 1;33(28):3137-43
pubmed: 26282663
Cancer. 2014 Oct 1;120(19):2955-64
pubmed: 24830599
BMC Cancer. 2014 Apr 23;14:286
pubmed: 24758513
Ann Intern Med. 2011 Jul 5;155(1):10-20
pubmed: 21727289
Lancet. 2003 Jan 11;361(9352):125-9
pubmed: 12531579
Ann Intern Med. 2016 Nov 15;165(10):700-712
pubmed: 27548583
Eur Radiol. 2016 Aug;26(8):2520-8
pubmed: 26560729
J Natl Cancer Inst. 2007 Dec 5;99(23):1782-92
pubmed: 18042936
Breast Cancer Res Treat. 2015 Jan;149(1):237-44
pubmed: 25503778
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1159-63
pubmed: 24991022
Biometrics. 2005 Jun;61(2):379-91
pubmed: 16011684